On May 29, Duality Biotherapeutics-B rose 5.16% in regular trading, trading at HK$219.8/share, with trading volume of approximately HK$110 million.

On the news front, the ASCO annual meeting officially opened on May 29, with the ADC track highlighted as a key focus area. The broader biotech sector rallied, with Innovent Bio up 10.42% and Akeso up 5.89%. Additionally, the company recently announced that its co-developed B7-H3 ADC candidate DB-1311/BNT324 with BioNTech completed first patient dosing in a global Phase III registrational study for metastatic castration-resistant prostate cancer. On May 12, Duality exercised its exclusive option to co-share U.S. R&D costs and commercialization economics for the asset.

The company also continued executing its share buyback program, repurchasing 30,000 shares on May 26 and 47,800 shares on May 28. Meanwhile, LAV Asset Management increased its position by 105,000 shares on May 20, raising its stake to 13.00%, reinforcing institutional confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)